Institute of Molecular Medicine and Cell Research, Faculty of Medicine, Albert Ludwigs University of Freiburg, Freiburg, Germany.
Spemann Graduate School of Biology and Medicine, Albert Ludwigs University of Freiburg, Freiburg, Germany.
Autophagy. 2021 Sep;17(9):2384-2400. doi: 10.1080/15548627.2020.1826716. Epub 2020 Oct 6.
Mutations in the gene result in autosomal dominant polycystic kidney disease (ADPKD), the most common monogenetic cause of end-stage renal disease (ESRD) in humans. Previous reports suggested that PKD1, together with PKD2/polycystin-2, may function as a receptor-cation channel complex at cilia and on intracellular membranes and participate in various signaling pathways to regulate cell survival, proliferation and macroautophagy/autophagy. However, the exact molecular function of PKD1 and PKD2 has remained enigmatic. Here we used -deficient mouse inner medullary collecting duct cells (mIMCD3) genetically deleted for , and tubular epithelial cells isolated from nephrons of doxycycline-inducible conditional knockout mice to show that the lack of caused diminished lysosomal acidification, LAMP degradation and reduced CTSB/cathepsin B processing and activity. This led to an impairment of autophagosomal-lysosomal fusion, a lower delivery of ubiquitinated cargo from multivesicular bodies (MVB)/exosomes to lysosomes and an enhanced secretion of unprocessed CTSB into the extracellular space. The TFEB-dependent lysosomal biogenesis pathway was however unaffected. -deficient cells exhibited increased activity of the calcium-dependent CAPN (calpain) proteases, probably due to a higher calcium influx. Consistent with this notion CAPN inhibitors restored lysosomal function, CTSB processing/activity and autophagosomal-lysosomal fusion, and blocked CTSB secretion and LAMP degradation in knockout cells. Our data reveal for the first time a lysosomal function of PKD1 which keeps CAPN activity in check and ensures lysosomal integrity and a correct autophagic flux. acCal: acetyl-calpastatin peptide; ADPKD: autosomal dominant polycystic kidney disease; CI-1: calpain inhibitor-1; CQ: chloroquine; Dox: doxycycline; EV: extracellular vesicles; EXO: exosomes; LAMP1/2: lysosomal-associated membrane protein 1/2; LGALS1/GAL1/galectin-1: lectin, galactose binding, soluble 1; LMP: lysosomal membrane permeabilization; mIMCD3: mouse inner medullary collecting duct cells; MV: microvesicles; MVB: multivesicular bodies; PAX8: paired box 8; PKD1/polycystin-1: polycystin 1, transient receptor potential channel interacting; PKD2/polycystin-2: polycystin 2, transient receptor potential cation channel; Tet: tetracycline; TFEB: transcription factor EB; VFM: vesicle-free medium; WT: wild-type.
PKD1 基因的突变导致常染色体显性多囊肾病(ADPKD),这是人类终末期肾病(ESRD)最常见的单基因病因。先前的报告表明,PKD1 与 PKD2/多囊蛋白-2 一起,可能作为纤毛和细胞内膜上的受体阳离子通道复合物发挥作用,并参与各种信号通路,以调节细胞存活、增殖和巨自噬/自噬。然而,PKD1 和 PKD2 的确切分子功能仍然是个谜。在这里,我们使用 基因敲除的 -/- 小鼠内髓集合管细胞(mIMCD3)和来自诱导型条件性 基因敲除小鼠肾单位的肾小管上皮细胞,证明缺乏 导致溶酶体酸化减少、LAMP 降解以及 CTSB/组织蛋白酶 B 加工和活性降低。这导致自噬体溶酶体融合受损,多泡体(MVB)/外泌体向溶酶体输送未被修饰的货物减少,未被加工的 CTSB 被分泌到细胞外空间的量增加。然而,TFEB 依赖性溶酶体生物发生途径不受影响。 -/- 细胞中钙依赖性 CAPN(钙蛋白酶)蛋白酶的活性增加,可能是由于钙内流增加。与这一观点一致,CAPN 抑制剂恢复了溶酶体功能、CTSB 加工/活性和自噬体溶酶体融合,并阻止了 基因敲除细胞中 CTSB 的分泌和 LAMP 降解。我们的数据首次揭示了 PKD1 的溶酶体功能,该功能可抑制 CAPN 活性,确保溶酶体完整性和正确的自噬流。acCal:乙酰钙蛋白酶抑制剂肽;ADPKD:常染色体显性多囊肾病;CI-1:钙蛋白酶抑制剂-1;CQ:氯喹;Dox:多西环素;EV:细胞外囊泡;EXO:外泌体;LAMP1/2:溶酶体相关膜蛋白 1/2;LGALS1/GAL1/galectin-1:凝集素,半乳糖结合,可溶性 1;LMP:溶酶体膜通透性;mIMCD3:小鼠内髓集合管细胞;MV:微泡;MVB:多泡体;PAX8:配对盒 8;PKD1/polycystin-1:多囊蛋白 1,瞬时受体电位通道相互作用;PKD2/polycystin-2:多囊蛋白 2,瞬时受体电位阳离子通道;Tet:四环素;TFEB:转录因子 EB;VFM:无泡培养基;WT:野生型。